Topic:

Diagnostics

Latest Headlines

Latest Headlines

Veran raised $12M to commercialize lung biopsy device

St. Louis, MO-based Veran Medical closed a $12 million financing round. The company, specializing in thoracic navigation an biopsy for early detection of lung cancer, will use the funds toward continued commercial expansion in the U.S. and international launch of the Veran Thoracic Navigation System.

Illumina, Reprogenetics to partner on in vitro fertilization gene-sequencing tech

Preimplantation genetic screening and diagnostics provider Reprogenetics is partnering with Illumina to use its next-generation sequencing tech in its analysis of embryos and infertility.

Mayo Clinic sues former exec for transferring trade secrets to Quest Diagnostics

Minnesota's Mayo Clinic is suing one of its former top executives for misappropriation of trade secrets as part of a plan to work for competitor Quest Diagnostics following a false retirement.

Beyond glucose: developing a diagnostic test for fructose intolerance

Researchers have identified a hormone that is associated with fructose, fibroblast growth factor 21 (FGF21), which increases rapidly in the blood after fructose ingestion. High FGF21 levels in the blood are associated with obesity, insulin resistance and nonalcoholic fatty liver disease in both humans and animals.

Eye care Dx maker RPS receives $28M in debt from OrbiMed

Sarasota, FL's RPS Diagnostics, maker of point-of-care diagnostic tests for eye conditions, announced Oct. 13 that it has closed a $28 million debt financing with healthcare-focused investment firm OrbiMed.

NanoString teams up with Brigham and Women's Hospital for cancer Dx development

NanoString Technologies is teaming up with Brigham and Women's Hospital to study genomic biomarkers and develop diagnostic tests for cancer, furthering the company's plans for accelerated growth.

Optos, NHS and academia in $16M partnership for eye disease diagnostic

Medical retinal imaging player Optos, the U.K. National Health Service and academics will participate in a £10 million ($16 million) collaboration to enable earlier detection of eye diseases that threaten vision.

NIH launches study of 'exceptional responders' to cancer therapies

The National Cancer Institute has launched a three to four year broad-based study of exceptional responders--patients who have had particularly good outcomes on cancer therapies as compared to their peers. The initiative was first considered a few years ago when it started to become easier to determine the molecular basis of why a particular patient's cancer responds to a molecularly targeted drug, but it is only being undertaken now.

23andMe customers must now opt in to find unknown close relatives via genetic test

Genetic testing company 23andMe--famous for getting on the bad side of the FDA--is reversing a planned policy that would automatically opt in customers to its close relatives program, which meant that by sending a saliva sample in for DNA analysis they could discover an unknown relative out of the blue. 

Researchers develop the first blood test to diagnose adult depression

Researchers have identified 9 RNA blood markers that can be used as part of a panel to diagnose depression. They said it is the first blood test to diagnose adult depression.